Arthrex wins FDA clearance for TightRope implant for pediatric ACL surgery

[Image courtesy of Arthrex]Arthrex announced today that it received FDA clearance for pediatric indications for its anterior cruciate ligament (ACL) TightRope implant.

Naples, Florida-based Arthrex designed TightRope for the surgical treatment of orthopedic injuries. According to a news release, it’s the first and only fixation device for ACL injuries cleared for pediatric use.

The company worked with orthopedic surgeons from the Hospital for Special Surgery (HSS). It developed techniques and instrumentation for ACL surgery with Dr. Frank Cordasco and Dr. Daniel Green of HSS. These include guides for addressing a growing population of young athletes facing ACL injuries.

“For more than a decade, Arthrex has worked closely with leading orthopedic surgeons from HSS to develop minimally invasive solutions for pediatric and young adolescent ACL surgery,” said Arthrex President and founder Reinhold Schmieding. “We are proud to partner with…

Read more
  • 0

Arthrex wins FDA clearance for TightRope implant for pediatric ACL surgery

[Image courtesy of Arthrex]Arthrex announced today that it received FDA clearance for pediatric indications for its anterior cruciate ligament (ACL) TightRope implant.

Naples, Florida-based Arthrex designed TightRope for the surgical treatment of orthopedic injuries. According to a news release, it’s the first and only fixation device for ACL injuries cleared for pediatric use.

Arthrex offers a portfolio of ACL TightRope fixation devices. It includes the ACL TightRope II implant and the TightRope attachable button system (ABS) and implant. It also features the FiberTag TightRope implant and the ACL Repair TightRope implant with FiberRing sutures.

The company worked with orthopedic surgeons from the Hospital for Special Surgery (HSS). It developed techniques and instrumentation for ACL surgery with Dr. Frank Cordasco and Dr. Daniel Green of HSS. These include guides for addressing a growing population of young athletes facing ACL injuries.

̶…

Read more
  • 0

Arthrex, Skytron partner on operative care facility needs

[Image from Arthrex/Skytron]Arthrex announced today that it partnered with Skytron to offer a range of total room solutions to address future needs of operative care facilities.

The Arthrex Synergy brand offers surgical imaging solutions for operating rooms around the world, allowing healthcare professionals to experience the value of interconnectivity, high-quality 4K image clarity and dynamic patient engagement applications to improve the quality of care while driving efficiency and controlling costs.

Skytron develops capital equipment, architectural systems and real-time clinical business intelligence for surgical, sterile processing and inpatient settings.

“Arthrex and Skytron share a common goal to improve surgical quality and patient care,” Arthrex Director of Imaging and Resection Sales Ryan Papa said in a news release. “This partnership allows us to offer the most advanced technology and operating room infrastructure in one package…

Read more
  • 0

Supreme Court’s Arthrex decision creates more review for patent owners — and more questions

Angeline Premraj is an attorney at Finnegan, Henderson, Farabow, Garrett & Dunner [Photo courtesy of Finnegan]

A Patent and Trademark Office director confirmation may solve some problems, but it’s not yet clear how discretionary review will continue to evolve.

Angeline Premraj, Troy Viger and Kathleen Daley, Finnegan

The U.S. Patent and Trademark Office’s inter partes review procedure is a popular avenue for challenging the validity of a patent outside of litigation. These procedures are overseen by a panel of three administrative patent judges (APJs) on the Patent Trial and Appeal Board (PTAB) at the Patent Office. In United States v. Athrex, the Supreme Court ruled that the “unreviewable authority” of APJs to conduct adversarial proceedings for challenging the validity of a patent violated the Constitution’s Appointments Clause. The Supreme Court also ruled that the appropriate remedy was to giv…

Read more
  • 0

U.S. Supreme Court kicks Arthrex case back to patent board

The U.S. Supreme Court ruled today that Patent Trial and Appeal Board judges are unconstitutionally appointed, but that greater supervision by the PTAB director would solve the problem.

The opinion in the case followed a 2019 appeals court ruling in the closely watched patent spat between Arthrex and Smith+Nephew (NYSE:SNN). In the original lawsuit, Smith+Nephew and ArthroCare (which Smith+Nephew acquired in 2014) petitioned for inter partes review of a patent secured by Arthrex. Three patent judges concluded that the patent was invalid.

Get the full story on our sister site, Medical Design & Outsourcing.

Read more
  • 0